We describe a highly sensitive heterogeneous enzymelinked immunoassay in which digoxin is used as the model analyte. An excess of enzyme-labeled monovalent antibody is incubated with sample containing the analyte such that all analyte is rapidly and quantitatively bound. Excess antibody that does not acquire a antigen in its binding site is rapidly removed from the mixture by passage through a porous affinity column containing immobilized analyte (or analog), present in vast excess. Only the labeled monovalent antibody that possesses an antigen in its binding site elutes from the column in the unbound fraction. The label present in this fraction is then quantified. Such an assay is extremely sensitive and obviates the limitations imposed by antibody affinity constants on homogeneous and competitive heterogeneous immunoassays. This assay can be performed rapidly and is readily amenable to automation.
There are numerous descriptions of assay configurations involving specific antibodies. All such assay configurations depend on the ability of an antibody to bind to a specific analyte. In homogeneous immunoassays (those not involving a separation step), the binding of an analyte by an antibody must induce a change in either the analyte or the antibody that can be subsequently detected, such as a change in the absorbance spectrum of an intrinsic or extrinsic fluorophore or chromophore (1) (2) (3) (4) or a change in the activity of an enzyme that has been covalently attached to either the antigen or the antibody (5-7). Although this approach is exceedingly simple, the fact that unbound analyte must be detected in the presence of bound analyte (or vice versa) imposes a limit on the ultimate sensitivity of the assay. In addition, these assays are typically performed in the competitive mode, so the ultimate sensitivity limit is dictated by the affinity constant of the antibody. Unfortunately, the equilibrium binding constant has an upper limit of 1010 L/mol and cannot be increased to improve the sensitivity of the assay.
Another series of immunoassay. configurations, which include a separation step (heterogeneous immunoassays), has been described to overcome some of the aforementioned limitations. The two archetypes of heterogeneous immunoassays are the radioinununoassay (RIA) (8) and enzymelinked immunosorbant assay (EusA) (9) . In the RIA and similar systems, a sample containing an unknown amount of unlabeled antigen is mixed with a known amount of antibody and labeled antigen. The system isallowed to react to near-equilibrium, and then antibody-bound antigen is separated from the unbound antigen. unbound fraction). This process generally requires 1 to 3 h and is labor intensive. More recently, the RIA approach has been modified for automation and speedby immobilizing the antibody on a porous support (10). After the sample containing unlabeled antigen is mixed with a known amount of labeled antigen, the sample is percolated through a column containing immobilized antibody. The proportion of free labeled antigen remaining in solution after the limited number of antibody sites has been ifiled is measured, and the bound antigen is released subsequently by chaotropic agents and quantified. Obviously, the more free unlabeled antigen in the original sample, the greater the amount of labeled antigen in the unbound fraction, and the less the amount of labeled antigen bound and subsequently eluted from the immobilized antibody matrix. In both the conventional RIA and the modified automated RIA, a major disadvantage is that the assay is still performed in a competitive mode; thus the ultimate limit of sensitivity is a strict function of the antibody affinity constant. The immunoassay procedure we describe here involves use of a separation step, but it avoids the competitive mechanism for assay development and thus increases the ultimate sensitivity limit. Thus the assay is extremely sensitive, being capable of quantifying i0'4 mol of analyte, and rapid, and could easily be automated.
In the usual

Materials and Methods
Materials
Human serum albumin (Grade V), /3-i-galactosidase (EC 3.2.1.23; Grade Vifi), ouabain, digoxin, and iodoacetamide were all from Sigma Chemical Co., St Louis, MO 63178. Synthesis of ouabain affinity resin. Ouabain (an analog of digoxin) was attached to an agarose matrix through a protein (human serum albumin), which serves as a spacer arm. First, we synthesized a ouabain-albumin conjugate, using a procedure similar to that described by Smith et al. (11) . Briefly, ouabain was oxidized with sodium metaperiodate, combined with human serum albumin, and then reduced with sodium cyanoborohydride. The resulting oua bain-albumin conjugate was immobilized on the Affi-Gel 10 according to the procedure described by the supplier. Coupling was performed at 4 #{176}C for 3 h in sodium phosphate buffer, 150 mmollL, pH 7.5, at a protein concentration of 10 mg/L, and then blocked with a 0.1 mol/L solution of ethanolamine adjusted to pH 8.0. The conjugate-resin was stored at 4#{176}C in sodium aside, 200 mg/L.
Affinity purification
of anti -digoxin. Digoxin-specific antibodies were immunopurified directly from whole rabbit serum (Cappel Laboratories) according to the following representative protocol. The ouabain affinity resin was packed into a 0.7 x 15cm column to give a bed volume of 6 mL, then equilibrated with phosphate-buffered saline. We applied 10 mL of antiserum, at < 1 mL/min. The column was washed with phosphate-buffered saline until the absorbance at 280 nm reached baseline (< 0.01 A). Antibody was then eluted from the column with 60 mL of 3 mol/L NH4SCN solution (pH adjusted to 7.5) and promptly dialyzed against four 2-L changes of phosphate-buffered saline at 4#{176}C. Preparation of Fab'-f3-galactosidase conjugate.
Affinitypurified antibodies were first converted into their respective F(ab')2 fragments by digestion with pepsin (12). After Fab'-f3-galactosidase conjugate co-chromatographed with the free 13-galactosidase; we pooled the entire peak of enzyme activity and subsequently immunopurified the conjugate on the affinity column containing immobilized ouabain. Measurement of digoxin. Digoxin was added to drug-free samples of normal human serum to give concentrations of 0, 1, 2, and 4 ng/mL. We added 50 L of the Fab'-/3-galactosidase conjugate to 1 mL of this serum, incubated the mixture at 25 #{176}C for 15 mm, and then passed 100 L of it through a 0.5 x 8 cm column of immobilized ouabain. The sample was eluted with 2.0 mL of phosphate-buffered saline at 4 mL/min . The amount of unbound Fab'-J3-galactosidase in the elute was measured by combining the 2.1 mL of eluate with 2.9 mL of phosphate-buffered saline containing o-nitrophenylgalactoside (final concentration of 2.5 mmoll L), then measuring the absorbance change at 405 nm at 37#{176}C.
Results and Discussion
Asshown both by rigorous thermodynamic argument and by experimental evidence, the underlying determinant of sensitivity of all homogeneous and heterogeneous competitive immunoassays is the affinity of the antibody for its antigen (14, 15). For "sandwich"-type assays, surface interactions and slow kinetics also generally influence and limit these assays. Figure 1 illustrates how the present heterogeneous immunoassay configuration circumvents these limitations. In this assay, excess labeled (enzyme) monovalent antibody is incubated with a sample containing the analyte. Even when the analyte concentration is extremely low, addition of a large excess of monovalent antibody impels the binding reaction to the right such that all analyte is bound rapidly. The excess labeled monovalent antibody, which doesnot acquire an antigen in its binding site, is removed by passing the mixture through a porous affinity column containing immobilized analyte (or its analog) present in vast excess. Only the labeled monovalent antibody that possesses an antigen in its binding site elutes from the column in the unbound fraction. The label (enzyme activity) in this fraction is then quantified and is directly proportional to the original concentration of analyte in the sample. This assay, therefore, is limited in sensitivity only by its detection system and not the antibody affinity constant for the analyte. We emphasize that native divalent antibodies or enzymes conjugated with multiple copies of monovalent antibodies will, however, limit the assay sensitivity to a competitive mode, because an antibody containing an antigen in one of its two binding sites cannot be differentiated from an antibody with no antigens-both will be retained by the affinity column.
As mentioned, to obtain the ultimate assay sensitivity, excess labeled monovalent antibody is pre-incubated with a sample containing the analyte. column eluate can be coupled to a spectrophotometer or fluorometer with automatic substrate dispensing, mixing, and kinetic measurement of color production. Virtually any detection system can be used. Enzymes that act on colonmetric, fluorometric, or bioluminescent substrates can be coupled to the monovalent antibodies for extreme sensitivity requirements. Another major feature of this approach is the lack of extensive column washing and elution steps commonly required for competitive heterogeneous immunoassays. On the other hand, a major disadvantage is that mterferents in biological specimens are not washed away.
We observed no such interferents in serum samples in these studies, and the use of Fab' fragments eliminated the potential problems commonly engendered by Clq and rheumatoid factors in immunoassays.
